TheraRadar
← Back
Data updated: Jul 17, 2026

NANJING

Generics
OncologyInfectious DiseaseImmunology Execution: Needs Improvement

NANJING is a generic drug manufacturer focused on Oncology, Infectious Disease, Immunology.

2020
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

NANJING at a Glance

  • Fast trial execution (10 months median completion)

NANJING's Key Drugs

NANJING's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

NANJING's Recent FDA Approvals

New NDA/BLA approvals for NANJING over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

NANJING's Therapeutic Areas

NANJING's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 67%
0 drugs Phase 3: 11 Phase 2: 12 Phase 1: 52
Infectious Disease 16%
0 drugs Phase 3: 5 Phase 2: 3 Phase 1: 2
Immunology 8%
0 drugs Phase 2: 3 Phase 1: 8
Gastroenterology 5%
0 drugs Phase 3: 1 Phase 2: 1 Phase 1: 3
Respiratory 4%
0 drugs Phase 2: 3 Phase 1: 1

NANJING's Top Competitors

NANJING's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, GSK, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Gastroenterology
GSK big-pharma
Respiratory, Infectious Disease, Oncology, Immunology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Infectious Disease, Gastroenterology
Pfizer big-pharma
Oncology, Infectious Disease, Immunology
Novartis big-pharma
Oncology, Respiratory, Immunology

NANJING Pipeline Snapshot

NANJING has 105 active clinical programs from ClinicalTrials.gov — 17 Phase 3, 22 Phase 2 and 66 Phase 1.

17
Phase 3
22
Phase 2
66
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/0 completed
  • • Speed: 10 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges